Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $56 from $54 and keeps a Buy rating on the shares. The firm is updating its Filspari market model following the April 13 FDA approval of Filspari in FSGS with a broader-than-expected label, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere’s Sparsentan Trial Delivers Mixed but Defining Results in Rare Kidney Disease
- Travere Therapeutics price target raised to $43 from $31 at Stifel
- Morning News Wrap-Up 4/14/26: Today’s Biggest Stock Market Stories!
- Travere Therapeutics rises 33.0%
- Midday Fly By: Amazon to buy Globalstar, J&J posts ‘beat and raise’ report